These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 25699211)
1. Effects of statins on TH1 modulating cytokines in human subjects. Cimato TR; Palka BA PeerJ; 2015; 3():e764. PubMed ID: 25699211 [TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol. Tani S; Nagao K; Hirayama A Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320 [TBL] [Abstract][Full Text] [Related]
5. Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients. Cimato TR; Palka BA Clin Transl Med; 2014; 3():14. PubMed ID: 24995121 [TBL] [Abstract][Full Text] [Related]
6. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274 [TBL] [Abstract][Full Text] [Related]
7. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107 [TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
10. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350 [TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893 [TBL] [Abstract][Full Text] [Related]
12. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW; Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001 [TBL] [Abstract][Full Text] [Related]
13. Intensive Statin Therapy Compromises the Adiponectin-AdipoR Pathway in the Human Monocyte-Macrophage Lineage. Gasbarrino K; Hafiane A; Zheng H; Daskalopoulou SS Stroke; 2019 Dec; 50(12):3609-3617. PubMed ID: 31648632 [TBL] [Abstract][Full Text] [Related]
14. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. Nishikido T; Oyama J; Keida T; Ohira H; Node K J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946 [TBL] [Abstract][Full Text] [Related]
15. Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy. Reiss AB; Arain HA; Kasselman LJ; Renna HA; Zhen J; Voloshyna I; DeLeon J; Carsons SE; Petri M Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438615 [No Abstract] [Full Text] [Related]
16. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
17. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
18. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study. Tani S; Nagao K; Hirayama A Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996 [TBL] [Abstract][Full Text] [Related]